MACROGENICS INC — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 81/100
What the filing says
MacroGenics and Sagard Healthcare Partners Funding Borrower SPE 2, LP amended their June 2025 Purchase and Sale Agreement effective May 1, 2026. Sagard paid MacroGenics $60 million on the amendment date, increasing the total purchase price to $130 million. The amendment also adds potential milestone payments to MacroGenics (amounts redacted) based on 2026 net sales of the royalty product under a License Agreement with Incyte, with payment due within 30 days of achievement notification.
Why this rating
The $60M payment is ~81% of company's $73.9M market cap—transformational liquidity event. Milestone upside adds optionality. Material cash infusion materially improves near-term runway and financial position.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.